Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update

There is overwhelming evidence that optimal adjuvant endocrine therapy for hormone sensitive breast cancer in postmenopausal women should include a third generation aromatase inhibitor (AI). On current evidence, adjuvant anstrozole or letrozole should be used upfront in such patients especially in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mokbel, Ramia, Karat, Isabella, Mokbel, Kefah
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1586206/
https://www.ncbi.nlm.nih.gov/pubmed/16981992
http://dx.doi.org/10.1186/1477-7800-3-31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1586206/
https://www.ncbi.nlm.nih.gov/pubmed/16981992
http://dx.doi.org/10.1186/1477-7800-3-31

Ejemplares similares